A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin XR Tablet (4 x 500 mg) in Healthy Fed Subjects
研究概览
地位
条件
详细说明
This is a randomized (the study medication is assigned by chance), open-label (physicians and participants know the identity of the assigned treatment), single-center, single-dose, 3-treatment, 3-way crossover (the same medications are provided to all participants but in different sequence) study of canagliflozin (CANA) and metformin extended release (MET XR) combined in one tablet, in comparison with tablets containing the individual components. Two Fixed Dose Combinations (FDCs) will be evaluated during the study (two types of tablets).
The tablets will be of the same strength (150 mg CANA/1,000 mg MET XR) and will be compared with equal doses of the individual drugs: canagliflozin (1 x 300 mg tablet) and metformin XR (4 x 500 mg tablets). Thus, there will be 3 treatment periods in the study: Treatment A: "Reference" treatment of individual components administered concurrently; Treatment B: CANA/MET XR FDC, formulation 1; and Treatment C: CANA/MET XR FDC, formulation 2. Approximately 42 healthy adult participants will be randomly assigned to 1 of the 3 treatments groups, and then each group will receive all three treatments in different sequences (3-way crossover). The study will consist of 3 phases: a Screening Phase of approximately 3 weeks, an Open-Label Treatment Phase consisting of 3 single-dose Treatment Periods of 5 days each separated by a washout period of 10 to 14 days and a Follow-up Phase occurring 7 to 10 days after the last study-related procedure of Treatment Period 3. The total duration of the study will be about 70 days for each participant.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Arizona
-
Tempe、Arizona、美国
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Must sign an informed consent document indicating they understand the purpose of the study and procedures
- Must have a body mass index (BMI) of between 18 and 30 kg/m2, inclusive
- Must have a body weight of not less than 50 kg - Must have a blood pressure between 90 and 140 mmHg inclusive, systolic, and no higher than 90 mmHg diastolic at screening
- Must have normal renal function and no evidence of kidney damage (including abnormalities in blood or urine tests)
Exclusion Criteria:
- History of or current clinically significant medical illness
- Use of any prescription or nonprescription medication (including vitamins and herbal supplements)
- History of clinically significant allergies, especially known hypersensitivity or intolerance to drugs or lactose
- Known allergy to heparin or history of heparin induced thrombocytopenia
- Donated blood or blood products or had substantial loss of blood within 3 months before screening
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Treatment A
Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 4 tablets of metformin extended release (MET XR), 500 mg each, administered together under fed conditions.
|
每片含有 300 毫克的卡格列净 (CANA),可口服(口服)。
其他名称:
每片含二甲双胍缓释剂 (MET XR),500 毫克,口服(口服)。
其他名称:
|
实验性的:治疗B
每个参与者将在进食条件下接受单剂 2 片 CANA/MET XR FDC,配方 1。
|
Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
|
实验性的:处理C
每个参与者将在进食条件下接受单剂 2 片 CANA/MET XR FDC,配方 2。
|
Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Plasma concentration of canagliflozin following administration of a single dose of study drug
大体时间:Predose, (before tablet intake) up to 72 hours after dose
|
Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body.
|
Predose, (before tablet intake) up to 72 hours after dose
|
Plasma concentration of metformin following administration of a single dose of study drug
大体时间:Predose, up to 36 hours after dose
|
Plasma concentrations of metformin are used to evaluate how long metformin stays in the body.
|
Predose, up to 36 hours after dose
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Percentage of participants with adverse events as a measure of safety and tolerability
大体时间:Screening, up to Day 10 of the follow-up period
|
Screening, up to Day 10 of the follow-up period
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
卡格列净,300 毫克的临床试验
-
Hospital Universitari Vall d'Hebron Research Institute未知
-
Gamaleya Research Institute of Epidemiology and...尚未招聘革兰氏阴性细菌感染 | 革兰氏阴性菌引起的菌血症 | 革兰氏阴性肺炎
-
McGill University Health Centre/Research Institute...招聘中
-
Basilea Pharmaceutica完全的尿路上皮癌英国, 大韩民国, 意大利, 加拿大, 法国, 西班牙, 德国, 美国, 匈牙利, 澳大利亚, 波兰, 瑞士, 捷克语, 奥地利
-
AstraZeneca主动,不招人转移性三阴性乳腺癌美国, 比利时, 意大利, 西班牙, 英国, 加拿大, 捷克语, 波兰, 法国, 大韩民国, 德国, 台湾, 葡萄牙, 荷兰, 爱尔兰